Literature DB >> 15229068

Medical decision making in antipsychotic drug choice for schizophrenia.

Johannes Hamann1, Bernadette Langer, Stefan Leucht, Raymonde Busch, Werner Kissling.   

Abstract

OBJECTIVE: The influence of patient and physician variables on antipsychotic drug choice for patients with schizophrenia was assessed.
METHOD: Interviews with 100 psychiatrists on drug choice for 200 patients suffering from schizophrenia were conducted. Data were analyzed by using multiple logistic regression.
RESULTS: Older physicians were up to five times more likely to prescribe first-generation antipsychotics. Patient variables did not influence treatment decisions significantly.
CONCLUSIONS: There is an urgent need for more research on clinical decision making and quality management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15229068     DOI: 10.1176/appi.ajp.161.7.1301

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  10 in total

1.  Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.

Authors:  Paul J Hauptman; Mark A Schnitzler; Jason Swindle; Thomas E Burroughs
Journal:  JAMA       Date:  2006-10-18       Impact factor: 56.272

2.  How do psychiatrists choose among different antipsychotics?

Authors:  Johannes Hamann; Grit Kolbe; Rudolf Cohen; Stefan Leucht; Werner Kissling
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

3.  Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia.

Authors:  Stefan Leucht; Johannes Hamann; Spyridon Siafis; Nicola Bursch; Katharina Müller; Lisa Schmid; Florian Schuster; Jakob Waibel; Tri Huynh; Florian Matthes; Alessandro Rodolico; Peter Brieger; Markus Bühner; Stephan Heres
Journal:  BMC Psychiatry       Date:  2022-06-17       Impact factor: 4.144

4.  How quickly do physicians adopt new drugs? The case of second-generation antipsychotics.

Authors:  Haiden A Huskamp; A James O'Malley; Marcela Horvitz-Lennon; Anna Levine Taub; Ernst R Berndt; Julie M Donohue
Journal:  Psychiatr Serv       Date:  2013-04-01       Impact factor: 3.084

5.  Improving outpatient treatment in schizophrenia: effects of computerized guideline implementation--results of a multicenter-study within the German research network on schizophrenia.

Authors:  B Janssen; S Ludwig; H Eustermann; R Menke; M Haerter; M Berger; G Adam; U Seemann; W Kissling; W Gaebel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-05-12       Impact factor: 5.270

6.  Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?

Authors:  Sameer Jauhar; Sinan Guloksuz; Olivier Andlauer; Greg Lydall; João Gama Marques; Luis Mendonca; Iolanda Dumitrescu; Costin Roventa; Nele De Vriendt; Jeroen Van Zanten; Florian Riese; Izu Nwachukwu; Alexander Nawka; Raphael Psaras; Neil Masson; Rajeev Krishnadas; Umberto Volpe
Journal:  BMC Psychiatry       Date:  2012-03-30       Impact factor: 3.630

7.  Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study.

Authors:  Rune A Kroken; Erik Johnsen; Torleif Ruud; Tore Wentzel-Larsen; Hugo A Jørgensen
Journal:  BMC Psychiatry       Date:  2009-05-16       Impact factor: 3.630

8.  Incorporating clinical guidelines through clinician decision-making.

Authors:  Paul R Falzer; Brent A Moore; D Melissa Garman
Journal:  Implement Sci       Date:  2008-02-29       Impact factor: 7.327

9.  System struggles and substitutes: A qualitative study of general practitioner and psychiatrist experiences of prescribing antipsychotics to children and adolescents.

Authors:  Andrea L Murphy; David M Gardner; Steve Kisely; Charmaine A Cooke; Stanley P Kutcher; Jean Hughes
Journal:  Clin Child Psychol Psychiatry       Date:  2015-11-27       Impact factor: 2.544

10.  Clinical Validity of Subjective Clinical Prognosis in First Episode Psychosis Schizophrenia Patients: An Analysis of Data from the European First Episode Schizophrenia Trial (EUFEST) Study.

Authors:  Valentin Petre Matei; Alexandra Ioana Mihăilescu; Iuliana Raluca Gheorghe; Ruxandra Grigoraş; Andrei Crasan; Alina Roșca; Ovidiu Popa-Velea
Journal:  Neuropsychiatr Dis Treat       Date:  2020-05-18       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.